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Abstract
Background: Qualitative evidence suggests patient-reported outcome (PRO) information is frequently absent from clinical
trial protocols, potentially leading to inconsistent PRO data collection and risking bias. Direct evidence regarding PRO trial
protocol content is lacking. The aim of this study was to systematically evaluate the PRO-specific content of UK National
Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme trial protocols.
Methods and Findings: We conducted an electronic search of the NIHR HTA programme database (inception to August
2013) for protocols describing a randomised controlled trial including a primary/secondary PRO. Two investigators
independently reviewed the content of each protocol, using a specially constructed PRO-specific protocol checklist,
alongside the ‘Standard Protocol Items: Recommendations for Interventional Trials’ (SPIRIT) checklist. Disagreements were
resolved through discussion with a third investigator. 75 trial protocols were included in the analysis. Protocols included a
mean of 32/51 (63%) SPIRIT recommendations (range 16–41, SD 5.62) and 11/33 (33%) PRO-specific items (range 4–18, SD
3.56). Over half (61%) of the PRO items were incomplete. Protocols containing a primary PRO included slightly more PRO
checklist items (mean 14/33 (43%)). PRO protocol content was not associated with general protocol completeness; thus,
protocols judged as relatively ‘complete’ using SPIRIT were still likely to have omitted a large proportion of PRO checklist
items.
Conclusions: The PRO components of HTA clinical trial protocols require improvement. Information on the PRO rationale/
hypothesis, data collection methods, training and management was often absent. This low compliance is unsurprising;
evidence shows existing PRO guidance for protocol developers remains difficult to access and lacks consistency. Study
findings suggest there are a number of PRO protocol checklist items that are not fully addressed by the current SPIRIT
statement. We therefore advocate the development of consensus-based supplementary guidelines, aimed at improving the
completeness and quality of PRO content in clinical trial protocols.
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Introduction
The value of assessing patient-reported outcomes (PROs) in
clinical trials has been emphasized by major international health-
policy and regulatory authorities, and by patients [1–3]. PROs are
increasingly selected as primary, secondary or exploratory
outcomes within clinical trials as they provide the patient’s
perspective on the physical, functional and psychological conse-
quences of treatment and the degree and impact of disease
symptoms (Table 1) [4]. If captured in a scientifically rigorous
way, PRO results may aid clinical decision-making [5], support
labelling claims [6] and influence healthcare policy [7]. It is
important, therefore, that details regarding PRO assessment are
included in the trial protocol, to ensure that PRO data is collected
and managed appropriately.
The trial protocol is a key document, which should provide
sufficient detail to facilitate understanding of the study design and
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administration, and enable appraisal of the trial’s scientific,
methodological and ethical rigor by funders and ethics committees
[8,9]. However, important information relating to study design,
implementation and dissemination is often omitted from trial
protocols [10–12]. This has led to the development of interna-
tional guidance for protocol developers and reviewers, in the form
of the SPIRIT 2013 statement (Standard Protocol Items:
Recommendations for Interventional Trials), which is aimed at
enhancing general study design, conduct, reporting and external
review [8,9]. PRO-specific information within trial protocols has
received little scrutiny to-date, however, recent qualitative
evidence suggests that it is sub-optimal [13]. This may lead to
variations in PRO measurement across trial sites, potentially
degrading data quality and biasing trial results [13]. Our objective
was to systematically review randomised controlled trial (RCT)
protocols including either a primary or secondary PRO outcome,
evaluating the completeness of their PRO-specific content using a
specially developed PRO protocol checklist. We also used the
SPIRIT tool to measure how complete the protocols were in broad
terms, to investigate whether levels of PRO content were
associated with general protocol completeness.
Methods
Ethics
The University of Birmingham ethical review board approved
this study (ERN_13-0047).
Protocol Selection
We reviewed protocols submitted to the National Institute for
Health Research (NIHR) Health Technology Assessment (HTA)
programme, reasoning they would provide a representative
snapshot of such documentation within the domain of health-care
research. The NIHR-HTA programme is the largest such funding
stream in the UK (comparable to the National Institutes of Health
in the US and the Australian New Zealand Clinical Trials Registry
in Australasia) and as a public interest funder, promotes the
inclusion of patient-centred outcomes in its research [14]. Two
investigators (BF, HDu) independently reviewed the NIHR-HTA
database (inception to August 2013, http://www.hta.ac.uk/
research/index.shtml) for RCTs with a primary or secondary
PRO endpoint. Disagreements regarding trial eligibility were
resolved through discussion with a third reviewer (DK/MC). The
most up-to-date trial protocols were retrieved for review, either
from the HTA database, the trial website, or via the named trial
representative (contacted by email, followed by one email
reminder after 2 weeks).
Data Extraction
Two investigators (DK, HDu) independently extracted the
following data from each protocol using a predesigned data
extraction form: year of protocol publication, the name(s) of the
PRO(s) used in the trial, whether the PRO was a primary or
secondary outcome, the trial setting (primary or secondary care)
and the clinical specialty.
Protocol Checklists
The completeness of the PRO-specific content of trial protocols
was assessed using a PRO protocol checklist (Table 2), generated
from 162 recommendations identified in our systematic review of
PRO-specific guidance for trial protocol writers [15]. Recommen-
dations were grouped into major categories comprising 33 PRO-
specific items for inclusion in a trial protocol. Individual
recommendations were retained under each item as subcategories
(illustrated in Figure 1). MC and DK constructed the initial
framework of the PRO protocol checklist, which was then
reviewed, amended where necessary, and subsequently approved
by an international expert external advisory group (MB, JB, RMB,
MK) (see Appendix S1 for the full checklist). The completeness of
general sections within each protocol was assessed using SPIRIT,
as a proxy measure of the overall strength of the protocol [8,9].
The SPIRIT resources include a checklist [8] containing 51
individual recommended protocol items, spread over 33 categories
and an accompanying explanatory paper [9] and website (www.
spirit-statement.org).
Protocol Review
Two investigators (DK, HDu) independently assessed the
content of the included protocols using the PRO and SPIRIT
checklists. For each trial protocol assessed, items on each checklist
were either described as ‘present’ or ‘absent’. One point was
assigned for each item ‘present’, giving a total score (maximum
achievable, 51 for SPIRIT and 33 for the PRO checklist). In
addition, for the PRO protocol checklist, the investigators also
determined whether all sub-categories were satisfied for each item
categorized as ‘present’. Therefore, PRO items that were marked
as ‘present’, but that failed to satisfy all of the appropriate sub-
categories were additionally tagged as ‘incomplete’. Levels of
investigator agreement were determined for both checklists.
Disagreements were resolved through discussion with a third
investigator (MC) if required.
Data Analysis
Analyses were performed using SAS V9.2 (SAS Institute, Cary
NC). Descriptive analyses were conducted on the number of PRO-
specific and SPIRIT checklist items present in the included
protocols. To explore factors associated with the inclusion of
PRO-specific protocol items, we performed a pre-specified
multiple regression analysis in which the dependent variable was
the PRO-specific protocol checklist score and the independent
variables were: whether the PRO was named as a primary or
secondary outcome, the trial setting, the clinical specialty and the
SPIRIT checklist score. 75 protocols were required to satisfy the
sample size requirement for this regression analysis (15 per co-
variate [16]). The relationship between the PRO-specific protocol
Table 1. Definitions.
Definitions:
Patient-Reported Outcome (PRO) – ‘‘… any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the
patient’s response by a clinician or anyone else.’’ [6]
Patient-Reported Outcome (PRO) – ‘‘… any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the
patient’s response by a clinician or anyone else.’’ [6]
doi:10.1371/journal.pone.0110229.t001
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Table 2. PRO-specific protocol checklist.
SPIRIT Section Item Number Description
Administrative information
P1 Roles & Responsibilities of PRO Personnel Identified?
Introduction
P2 Background PRO-specific information provided?
P3 PRO-specific rationale provided?
P4 PRO-specific hypothesis provided?
P5 PRO-specific objectives stated (in relation to dimensions, population
and timeframe)?
Methods: Participants, interventions and outcomes
P6 Details & rational of PRO study sample/setting provided?
P7 PRO considerations discussed in the eligibility criteria?
P8 PRO endpoint specified?
P9 Timing of PRO assessments specified?
P10 Timing of PRO assessments justified?
P11 PRO sample size discussed & justified?
Methods: Assignment of interventions (for controlled
trials)
P12 PROs discussed in relation to blinding?
Methods: Data collection, management and analysis
P13 PROM identified & described?
P14 Choice of PROM justified in relation to study hypothesis?
P15 Choice of PROM justified in relation to measurement properties?
P16 Choice of PROM justified in relation to acceptability & patient
burden?
P17 PRO data collection plan included?
P18 PRO data collection guidelines/training information provided for trial
personnel?
P19 Plans to minimise avoidable missing PRO data provided?
P20 PRO-specific Quality Assurance (QA) described?
P21 PRO Statistical Analysis Plan provided?
P22 Plans to address multiplicity of PRO data provided?
P23 PRO clinical significance defined?
P24 Statistical methods to deal with missing PRO data defined?
Monitoring
P25 PRO data monitoring defined?
P26 Plan for the identification and management of PRO Alerts included?
Ethics and dissemination
P27 PRO-specific consent information provided?
P28 PRO-specific confidentiality procedures described?
P29 PRO dissemination policy outlined?
Appendices
P30 PRO information included in consent materials?
P31 PRO assessment checklist and/or flowsheet provided in appendix?
P32 Exact version of PROM provided in CRF/appendix (with translated
versions if appropriate)?
P33 PROM completion instructions provided in CRF/appendix?
Abbreviations: SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials; PRO, patient-reported outcome; PROM, patient-reported outcome measure;
CRF, case report form.
doi:10.1371/journal.pone.0110229.t002
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checklist score and the candidate explanatory variables was
assessed using a backward stepwise selection process with
a=0.05 as criteria for model inclusion.
Results
At the time of the review (August 2013) 459 studies were listed
on the HTA database, of which 284 fulfilled the inclusion criteria.
As our sample size requirement was 75, we restricted our review to
the 75 most recent trial protocols to provide an up-to-date picture
of the PRO-specific content in such documentation. Levels of
investigator agreement for both checklists were high (85.77% for
SPIRIT and 86.11% for the PRO checklist) and all disagreements
were resolved through discussion. Characteristics of the included
protocols are presented in Table 3. A PRO was the primary
outcome in 41%; 38% were conducted in a primary care setting,
51% were conducted in secondary care and 11% were conducted
in both. In total, 251 different PRO measures were used across the
included trials (Appendix S2), the most common being the five
dimension European Quality of Life instrument (EQ-5D), the
Short-Form Health Survey 12-item (SF-12) and 36-item (SF-36)
questionnaires and the Hospital Anxiety and Depression Scale
(HADS).
Adherence to SPIRIT and PRO Checklists
Protocols included a mean of 32/51 (63%) SPIRIT recommen-
dations (range 16–41, SD 5.62) and 11/33 (33%) PRO-specific
items (range 4–18, SD 3.56). Protocol adherence to individual
SPIRIT and PRO checklist items is presented in Figures 2 and 3,
summarized in Table 4, and discussed below.
Administrative information
SPIRIT. Protocols routinely included general administrative
information including: the project title (97% of protocols), protocol
version (99%), trial sponsor (88%) and coordinating centre/
steering committee details (84%). Just under two-thirds presented
information regarding trial registration (57%) or sources of funding
(64%). Few (8%) made it clear who had contributed to the
production of the protocol.
PRO-specific. Five protocols (7%) included administrative
information regarding the roles and responsibilities of trial
personnel involved in the design and collection of PRO data.
Introduction
SPIRIT. Almost all protocols (99%) included general back-
ground information in the introduction and outlined the trial
rationale or included specific trial objectives or hypotheses (97%).
PRO-specific. Just under half of the protocols (49%)
provided background details regarding the relevant existing
PRO research (or lack of) in the area of interest, but very few
(8%) included a rationale for the collection of PRO data within the
trial. Over two-thirds also included PRO-specific objectives (77%),
however, over one-third of these (39%) were incomplete, for
example, details regarding the PRO dimensions under investiga-
tion or the timeframe of interest were often missing. In addition,
less than one-third of protocols (19%) provided a PRO-specific
hypothesis.
Methods: Participants, Interventions and Outcomes
SPIRIT. Just over two-thirds of protocols (68%) included a
description of the study setting(s), whilst 100% included general
eligibility criteria. Protocols routinely included information on trial
recruitment methods (87%), interventions (97%), outcomes (83%)
and sample size requirements (97%). Half of the protocols (50%)
presented criteria for discontinuing or modifying interventions,
strategies to improve adherence to intervention protocols and
included a participant time schedule. Less than one-third (29%)
discussed relevant concomitant care and interventions.
PRO-specific. Just under half of the included protocols (45%)
discussed PRO-specific eligibility considerations. None provided a
description/rationale addressing which trial participants were
eligible for PRO analysis. There was routine reporting of the
timing of PRO assessments (97%), but justification for PRO
timings was rarely provided (7%). PRO endpoints were described
in nearly all protocols (97%), however, in more than one-third
(35%) the information provided was incomplete, for example, the
primary time-point for analysis, or an outline of the constructs
used to evaluate the intervention (e.g. overall quality of life, or a
specific domain/symptom) were frequently absent. Similarly,
whilst PRO sample size requirements were provided in approx-
imately half of the included protocols (51%), 20% of these failed to
justify the assumptions of PRO analyses outlined.
Methods: Assignment of Interventions (for controlled
trials)
SPIRIT. All of the included trials were controlled and 61%
employed some form of blinding. Most protocols detailed methods
of allocation sequence generation and concealment (87% and 81%
respectively), but few outlined who would assign participants to
interventions (35%). Almost all protocols (96%) identified who
would be blinded to the trial interventions, but less than one-third
(28%) discussed the circumstances under which un-blinding was
permissible.
Methods: Data Collection
SPIRIT. Most protocols (96%) provided general plans for the
assessment and collection of trial outcomes and over two-thirds
Figure 1. PRO protocol checklist item ‘P8’ and associated sub-
categories.
doi:10.1371/journal.pone.0110229.g001
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(80%) described proposed strategies for the promotion of
participant retention.
PRO-specific. PRO measures (PROMs) were always named
(100%), but details regarding the measures were frequently
missing, for example, the number of items/domains, methods
for instrument scaling/scoring and estimated average completion
time. The choice of PROM was rarely justified, whether in
relation to the study hypothesis (justified in 41% of protocols),
measurement properties (justified in 37%), or in relation to
participant acceptability/burden (justified in 15%). Where some
justification (of any type) was present (n = 33 protocols, 44%), it
was commonly incomplete, for example, often information was not
provided regarding the evidence-base (or lack of) for all
measurement properties for a given tool, or for all tools used
within a trial, and references were regularly absent. Brief
information surrounding the plans for PRO data collection was
included in 84% of protocols, but again elements were often
absent, for example, there was a lack of information on who
should administer the PROM and the level of assistance allowed
during assessment, whether proxy assessment was permissible and
where PRO assessment would take place. Just under half of the
protocols (47%) detailed plans to minimize levels of avoidable
missing PRO data. Finally, only 8% of protocols provided
information surrounding PRO data collection guidelines and/or
training for trial personnel.
Methods: Management and Analysis
SPIRIT. Data management issues were discussed in 87% of
protocols. Statistical methods for analysing (non-PRO) primary
and secondary outcomes were routinely included in almost all
(99%) protocols and over two-thirds discussed methods of
additional analysis (71%) (e.g. subgroup analysis) and the handling
of protocol non-adherence (72%).
PRO-specific. PRO-specific quality assurance issues were
discussed in 60% of protocols. A PRO statistical analysis plan was
provided in 96% of protocols, however, very few (1%) provided
plans to address multiplicity of PRO data or were explicit about
PRO clinical significance levels; and less than half (45%) detailed
statistical methods to deal with missing PRO data.
Table 3. Characteristics of included protocols (N = 75).
Characteristic Protocols, No. (%)
Year
2012 29 (39)
2013 46 (61)
Study PRO endpoint & setting
PRO 1u Outcome 31 (41)
Primary care setting 29 (38)
Secondary care setting 38 (51)
Both primary & secondary care 8 (11)
Clinical Research Area
Mental Health 15 (20)
Neurology 8 (11)
Orthopaedics; Paediatric; Vascular 5 (7)
Obstetrics & Gynaecology; Oncology; Respiratory; 4 (5)
Cardiology; Physical Activity; Smoking Cessation 3 (4)
Falls Prevention; Gastroenterology; Weight Loss 2 (3)
Aids; Colorectal; Dermatology; Diabetes; Elderly Care; Emergency Services; General Practice; Hepatology;
Nephrology; Urology
1 (1)
PROMS#
European QOL instrument (EQ-5D) 56 (75)
Short-Form Health Survey 36-item (SF-36) 13 (17)
Short-Form Health Survey 36-item (SF-12) 12 (16)
Hospital Anxiety and Depression Scale (HADS) 9 (12)
Patient Health Questionnaire 9 (PHQ-9) 6 (8)
Pediatric Quality of Life Inventory (PEDSQL); 5 (7)
Epworth Sleepiness Scale (ESS); Beck Depression Inventory (BDI); Generalised Anxiety Disorder (GAD-7); Calgary
Sleep Apnoea Quality of Life Index (SAQLI); Carer/Proxy/Parent Completion EQ-5D
3 (4)
Client Services Receipt Inventory (CSRI); WHOQOL-BREF Secondary; The Lubben Social Network Scale (LSNS); Resource
Use questionnaire; Morisky Medication Adherence Scale; International Physical Activity Questionnaire (IPAQ); Clinical
Outcomes in Routine Evaluation Outcome Measure (CORE-OM); Falls Efficacy Scale; Nottingham Activities of Daily Living
(NEADL); Olerud & Molander Ankle Score (OMAS)
2 (3)
# PROMS listed used in .1 protocol. Total Number of PROMS used n = 251. A full list appears in Appendix S2. Abbreviations: PRO, patient-reported outcome; PROM,
patient-reported outcome measure; QOL, quality of life.
doi:10.1371/journal.pone.0110229.t003
PRO Protocol Review
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Monitoring
SPIRIT. Information regarding the Data Monitoring Com-
mittee, interim analysis, stopping guidelines and trial auditing
arrangements was included in 85%, 67% and 55% of protocols
respectively. Plans for monitoring and managing adverse events/
harms were included in 85% of protocols.
PRO-specific. PRO-specific data monitoring issues were
discussed in 1% of protocols. Plans for the identification and
management of ‘PRO Alerts’ - where trial personnel encounter
‘concerning’ individual participant PRO data that may require a
prompt response [17] - were included in 11% of protocols.
Ethics and Dissemination
SPIRIT. Inclusion of ethics approval information (88%),
informed consent/assent procedures (89%) and a dissemination
policy (75%) was common. Just under two-thirds of protocols
discussed confidentiality (63%) and ancillary and post-trial care
(63%). There was, however, little consideration of authorship
eligibility (36%), access to trial data (3%) or declaration of interests
(0%).
PRO-specific. A third of protocols discussed PRO-specific
dissemination (33%), but few (1%) tackled PRO consent or
confidentiality issues.
Appendices
SPIRIT. Fifty-one (68%) of the included protocols included
patient information and consent materials in an appendix.
PRO-specific. PRO-specific information was included in
59% of patient information sheets. An exact version of the
PROM(s) employed by the study was included in 11% of
appendices; none included a PRO assessment checklist/flowchart.
Determinants of Differences in PRO-specific Protocol
Content
Table 5 summarizes the findings from our exploratory multiple
regression analysis, which investigated predictors of differences in
the PRO-specific checklist score between protocols. In the final
model, only the nature of the PRO endpoint (primary versus
secondary) was significant (P,.001), suggesting that protocols
describing trials with a primary PRO include on average 5.00
(95% CI 3.79 to 6.21) additional recommended PRO-specific
items compared to those employing a secondary PRO endpoint.
There were no significant associations between the PRO checklist
score and the year of protocol publication (P = .18), the trial setting
(P= .08), the clinical specialty (P = .14) or the SPIRIT checklist
score (P = .17). The full (first) model is presented in Appendix S3.
Figure 2. Protocol adherence to individual SPIRIT items. *Denominator adjusted as n = 46 blinded trials included in sample.
doi:10.1371/journal.pone.0110229.g002
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Discussion
Summary of Findings
To our knowledge, this is the first study to evaluate the PRO-
specific content of trial protocols. We found that routine inclusion
of PRO information was poor (33%) and that over half (61%) of
included PRO items were incomplete. Trials with a primary PRO
endpoint tended to routinely include slightly more PRO informa-
tion in their protocols (mean 43%). PRO protocol content was not
associated with general protocol completeness; thus, protocols
judged as relatively ‘complete’ using SPIRIT were still likely to
have omitted a large proportion of PRO checklist items.
Our findings are concordant with the prevailing empirical
evidence that important general methodological details are often
missing from protocols [10–12,18,19]. On average, the reviewed
protocols failed to include over one-third (37%) of the recom-
mended protocol items outlined in SPIRIT [8] and over two-thirds
(67%) of PRO checklist items. Our results also concur with
qualitative data drawn from UK-based trial personnel, suggesting
a widespread lack of PRO-specific information in clinical trial
protocols and training [13].
Omission of recommended PRO content in trial protocols could
lead to inconsistent assessment of important patient-centred
outcomes [13], risking biased and unreliable trial results, and
lessening the impact of PROs on routine clinical care. This
practice may mislead clinical or health policy decision-making,
reduce the value of patient participation in trials and waste limited
healthcare and research resources: this is unethical [20].
The particularly low PRO checklist compliance we observed in
our study is unsurprising, as evidence suggests existing PRO
guidance for protocol writers is difficult to access and lacks
consistency [15]. Until such time as this guidance improves, it may
be difficult for researchers to effectively incorporate PRO
information into their protocols. Unfortunately, our findings also
suggest that PRO-specific protocol items are either not addressed
by the current SPIRIT checklist (for example, the management of
‘PRO Alerts’ [17]), or are addressed only partially, such that fuller
explanation is warranted to provide meaningful guidance to
protocol developers who may not be familiar with PRO
methodology (for example, approaches to minimise avoidable
missing PRO data). The scope and number of additional PRO
items, and the current lack of coherence in the guidance literature,
justifies the need for supplementary PRO-specific guidelines. The
PRO protocol checklist developed for this study could be
incorporated into such guidelines. It is important to note, however,
in designing the PRO checklist we deliberately sought to retain all
PRO protocol guidance extracted in our review [15], without
making a judgment on which items might be essential and which
may be optional, or if the essential versus optional items might
differ depending on whether a PRO was a primary or secondary
outcome. The checklist therefore provides the research community
with a comprehensive starting point, as opposed to a definitive
tool; and does not amount to an international consensus, but
rather represents an approximation of it for illustrative purposes.
The next step would be for the PRO protocol checklist be
subjected to a formal international consensus process to ensure
that it provides appropriate and consistent guidance to protocol
developers and focuses on only those PRO-specific protocol items
that are deemed most important by the scientific community and
other relevant stakeholders, including patients. Following this
process, the checklist may prove a valuable addition to formal
PRO protocol guidelines, aimed at improving the completeness
and quality of PRO content in clinical trial protocols.
Figure 3. Protocol adherence to individual PRO items. *Denominator adjusted as n= 46 blinded trials included in sample.
doi:10.1371/journal.pone.0110229.g003
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Table 4. Protocol adherence to individual SPIRIT and PRO checklist items (Sample, n = 75).
SPIRIT CHECKLIST TOTAL PRO CHECKLIST COMPLETE INCOMPLETE TOTAL
Administrative Information
ITEM 1: Title 97.33%
ITEM 2A: Trial identifier and registry
name
57.33%
ITEM 2B: WHO Trial Registration Data
Set
0.00%
ITEM 3: Protocol version 98.67%
ITEM 4: Funding 64.00%
ITEM 5A: Protocol contributors 8.00%
ITEM 5B: Trial sponsor information 88.00%
ITEM 5C: Role of sponsor and
funders in study
1.33%
ITEM 5D: Roles of coordinating
centre/steering committee etc.
84.00%
ITEM 1: Roles & Responsibilities
of PRO personnel identified?
0.00% 6.67% 6.67%
INTRODUCTION
ITEM 6A: Description of research
question and justification for
undertaking the trial
98.67%
ITEM 6B: Explanation for choice
of comparators
64.00%
ITEM 2: Background PRO-specific
information provided?
24.00% 25.33% 49.33%
ITEM 3: PRO-specific rationale
provided?
0.00% 8.00% 8.00%
ITEM 7: Objectives 97.33%
ITEM 4: PRO-specific hypothesis
provided?
17.33% 1.33% 18.67%
ITEM 5: PRO-specific objectives
stated (in relation to dimensions,
population and timeframe)?
38.67% 38.67% 77.33%
ITEM 8: Description of trial design 96.00%
Methods: Participants,
Interventions and Outcomes
ITEM 9: Study setting 68.00%
ITEM 6: Details & rationale of PRO
study sample/setting provided?
0.00% 0.00% 0.00%
ITEM 10: Eligibility criteria 100.00%
ITEM 7: PRO considerations
discussed in the eligibility criteria?
12.00% 33.33% 45.33%
INTERVENTION
ITEM 11A: Interventions for each
group
97.33%
ITEM 11B: Criteria for
discontinuing or modifying
allocated interventions
50.67%
ITEM 11C: Strategies to improve
adherence to intervention
protocols
50.67%
ITEM 11D: Relevant concomitant
care and interventions
29.33%
ITEM 12: Outcomes 82.67%
ITEM 8: PRO endpoint specified? 62.67% 34.67% 97.33%
ITEM 13: Participant timeline 50.67%
ITEM 9: Timing of PRO
assessments specified?
0.00% 97.33% 97.33%
PRO Protocol Review
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Table 4. Cont.
SPIRIT CHECKLIST TOTAL PRO CHECKLIST COMPLETE INCOMPLETE TOTAL
ITEM 10: Timings of PRO
assessments justified?
4.00% 2.67% 6.67%
ITEM 14: Sample size 97.33%
ITEM 11: PRO sample size
discussed & justified?
30.67% 20.00% 50.67%
ITEM 15: Recruitment 86.67%
Methods: Assignment of
interventions (for controlled
trials)
ITEM 16A: Allocation Sequence
generation
86.67%
ITEM 16B: Allocation concealment 81.33%
ITEM 16C: Allocation
Implementation
34.67%
BLINDING
ITEM 17A: Who will be blinded
after assignment to interventions*
96.23%
ITEM 17B: circumstances under
which unblinding is permissible*
28.30%
ITEM 12: PROs discussed in
relation to blinding?*
3.77% 0.00% 3.77%
Methods: Data Collection,
Management and Analysis
ITEM 18A: Plans for assessment
and collection of outcomes
96.00%
ITEM 13: PROM identified &
described?
1.33% 98.67% 100.00%
ITEM 14: Choice of PROM
justified in relation to study
hypothesis?
9.33% 32.00% 41.33%
ITEM 15: Choice of PROM
justified in relation to
measurement properties?
5.33% 32.00% 37.33%
ITEM 16: Choice of PROM
justified in relation to
acceptability & patient burden?
2.67% 12.00% 14.67%
ITEM 17: PRO data collection
plan included?
1.33% 82.67% 84.00%
ITEM 18: PRO data collection
guidelines/training information
provided for trial personnel?
0.00% 8.00% 8.00%
ITEM 19: Plans to minimise
avoidable missing PRO data
provided?
34.67% 12.00% 46.67%
ITEM 18B: Plans to promote
participant retention
80.00%
ITEM 19: Data management 86.67%
ITEM 20: PRO-specific Quality
Assurance (QA) described?
0.00% 60.00% 60.00%
ITEM 20A: Statistical methods
for analysing primary and
secondary outcomes
98.67%
ITEM 21: PRO Statistical
Analysis Plan provided?
77.33% 18.67% 96.00%
ITEM 22: Plans to address
multiplicity of PRO data
provided?
1.33% 0.00% 1.33%
ITEM 23: PRO clinical
significance defined?
0.00% 1.33% 1.33%
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Table 4. Cont.
SPIRIT CHECKLIST TOTAL PRO CHECKLIST COMPLETE INCOMPLETE TOTAL
ITEM 24: Statistical methods
to deal with missing PRO data
defined?
21.33% 24.00% 45.33%
ITEM 20B: Methods for any
additional analyses (e.g.,
subgroup and adjusted analyses)
70.67%
ITEM 20C: analysis population
relating to protocol non-adherence
72.00%
MONITORING
ITEM 21A: Composition of Data
Monitoring Committee (DMC) etc.
85.33%
ITEM 21B: Description of any
interim analyses and stopping
guidelines
66.67%
ITEM 25: PRO data monitoring
defined?
1.33% 0.00% 1.33%
ITEM 22: Harms 85.33%
ITEM 26: Plan for the identification
and management of PRO alerts
included?
8.00% 2.67% 10.67%
ITEM 23: auditing 54.67%
Ethics and Dissemination
ITEM 24: research ethics approval 88.00%
ITEM 25: protocol amendments 16.00%
ITEM 26A: consent or assent 89.33%
ITEM 26B: consent or assent
(Biological specimens)
8.00%
ITEM 27: PRO-specific consent
information provided?
1.33% 0.00% 1.33%
ITEM 27: Confidentiality 62.67%
ITEM 28: PRO-specific
confidentiality procedures
described?
4.00% 0.00% 4.00%
ITEM 28: Declaration of interests 0.00%
ITEM 29: Access to data 2.67%
ITEM 30: Ancillary and post-trial
care
62.67%
ITEM 31A: Dissemination policy 74.67%
ITEM 31B: Authorship eligibility
guidelines
36.00%
ITEM 29: PROs dissemination
policy outlined?
33.33% 0.00% 33.33%
ITEM 31C: Plans, if any, for
granting public access to the
full protocol
0.00%
APPENDICES
ITEM 32: Informed consent
materials
68.00%
ITEM 30: PRO information
included in consent materials?
25.33% 33.33% 58.67%
ITEM 33: Biological specimens 18.67%
ITEM 31: PRO assessment
checklist and/or flowsheet
provided in appendix?
0.00% 0.00% 0.00%
ITEM 32: Exact version of
PROM provided in CRF/appendix
(with translated versions if
appropriate)?
10.67% 0.00% 10.67%
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Strengths and Weaknesses
The major strength of this study is its use of systematic methods
and multiple reviewers at all stages. The SPIRIT 2013 statement
was developed with comprehensive stakeholder involvement using
rigorous and systematic methodology [21]. The PRO-specific
checklist used in this study was developed by experts in the field, is
supported by a systematic review of existing guidance [15] and
demonstrated high levels of inter-rater agreement, however, it is
yet to undergo a formal consensus process or validation. Both the
PRO and SPIRIT checklists are still very recent and would not
have been available to the developers of many of the included
protocols, therefore validation of our findings in a contemporary
sample of protocols is required. Our protocol sample is relatively
small, and all describe trials that are UK-led (within a single
funding stream), restricting generalizability. Nevertheless, the
sample includes studies focusing on a range of clinical specialties,
conducted in a variety of healthcare settings and employing a
broad spectrum of PROs, thus enhancing external validity.
Finally, it is possible that the trial protocols from other funding
bodies are more advanced, in PRO terms, than those included in
our review; although this is unlikely given the stature and nature of
the HTA programme, further work would be needed to test this
hypothesis.
Conclusions
The PRO components of HTA clinical trial protocols require
improvement. Detailed instructions on the PRO rationale/
hypothesis, data collection methods, training and management
were often absent from protocols, even where the PRO was the
primary outcome. This low compliance is unsurprising as existing
PRO guidance for protocol writers lacks consistency and is difficult
to access, whilst PRO-specific protocol items are not fully
addressed by the current SPIRIT statement. There is a need for
consensus-based supplementary guidelines outlining recom-
mended standard PRO content for inclusion within trial protocols.
Supporting Information
Appendix S1 Full PRO protocol checklist.
(XLSX)
Appendix S2 Full list of PROMs used across included
protocols.
(XLSX)
Appendix S3 Full multiple regression model.
(XLSX)
Checklist S1 PRISMA Checklist.
(DOC)
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